MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Non Operating Interest Expenses of $241.81 for Q3 2022, down 99.82% year-over-year from $132679.2 in Q3 2021, and down 99.96% quarter-over-quarter from $583805.8 in Q2 2022.
Analysis
MindWalk Holdings (HYFT) Non Operating Interest Expenses (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Non Operating Interest Expenses for 3 consecutive years, with $241.81 the latest figure, recorded in Q3 2022.
- In Q3 2022, Non Operating Interest Expenses fell 99.82% year-over-year to $241.81; the TTM figure through Jul 2022 stood at $584431.3 (down 8.98% YoY), while the FY2022 annual figure was $584270.8, up 10.59% from the prior year.
- Non Operating Interest Expenses fell to $241.81 in Q3 2022 per HYFT's latest filing, from $583805.8 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $583805.8 in Q2 2022 and bottomed at $180.14 in Q1 2022.
- Historically, Non Operating Interest Expenses has averaged $138961.6 across 3 years, with a median of $132679.2 in 2021.
- On a YoY basis, Non Operating Interest Expenses climbed as much as 449.75% in 2021 and fell as far as 99.89% in 2021.
- MindWalk Holdings' Non Operating Interest Expenses stood at $193620.3 in 2020, then sank by 99.89% to $203.63 in 2021, then climbed by 18.75% to $241.81 in 2022.
- Business Quant data shows HYFT's Non Operating Interest Expenses at $241.81 in Q3 2022, $583805.8 in Q2 2022, and $180.14 in Q1 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | 20.27 Mn |
| 10 | MindWalk Holdings | 60.76 Mn | 52.48 Mn | 1.82 Mn | -3,647.53 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -3,647.53 |
| Apr 30, 2025 | -2,810.91 |
| Jan 31, 2025 | -2,113.28 |
| Oct 31, 2024 | -2,196.87 |
| Apr 30, 2024 | -2,950.08 |
| Jan 31, 2024 | -3,698.61 |
| Oct 31, 2023 | -3.69 Mn |
| Jul 31, 2023 | -3,746.02 |
| Apr 30, 2023 | -19,954.33 |
| Oct 31, 2022 | -1.51 Mn |
| Jul 31, 2022 | 241,810.94 |
| Apr 30, 2022 | -532,160.16 |
| Jan 31, 2022 | 180,138.61 |
| Oct 31, 2021 | 203,632.07 |
| Jul 31, 2021 | 132,679.23 |
| Apr 30, 2021 | 147,891.85 |
| Jan 31, 2021 | 167,821.63 |
| Oct 31, 2020 | 128,429.27 |
| Apr 30, 2020 | 3,540.01 |
| Jan 31, 2020 | 105,934.24 |